Solara Active Pharma Sciences Quarterly Results for Trading Insights
In Mar 2026, Solara Active Pharma Sciences (SOLARA) reported revenue ₹393 Cr and net profit ₹10 Cr — revenue +40.9% YoY. For annual financials, live price and key ratios, visit Solara Active Pharma Sciences share price chart.
SOLARA Quarterly Results — Revenue, Profit & EPS Highlights
Solara Active Pharma Sciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore SOLARA share price charts to track price trends across different timeframes.
- Revenue of ₹393 Cr in Mar 2026 (+25.2% vs Sept 2025, +40.9% vs Mar 2025)
- Net Profit of ₹10 Cr in Mar 2026 (+200.0% vs Sept 2025, +600.0% vs Mar 2025)
- EBITDA of ₹63 Cr in Mar 2026 (+80.0% vs Sept 2025)
- Operating Margin of 15.0% in Mar 2026 (+4.0pp vs Sept 2025)
- Earnings Per Share of ₹2.20 in Mar 2026 (+193.2% vs Sept 2025)
Solara Active Pharma Sciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SOLARA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 393 | 314 | 279 | 320 | 349 | 25.2% | 40.9% |
| Net Profit (₹ Cr) | 10 | -10 | -2 | 11 | -17 | - | - |
| EBITDA (₹ Cr) | 63 | 35 | 51 | 58 | 31 | - | - |
| EPS (₹) | 2.20 | -2.36 | -0.93 | 2.46 | -3.98 | - | - |
| Operating Margin (%) | 15.0% | 11.0% | 17.0% | 18.0% | 9.0% | - | - |
SOLARA Share Price Trend — 1-Year Movement Across Quarterly Results
Solara Active Pharma Sciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with Solara Active Pharma Sciences value estimation to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SOLARA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Solara Active Pharma Sciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores